Skip to main content
SpringerLink
Log in

Classification of Pulmonary Hypertension

  • Chapter
Book cover Pulmonary Hypertension

Part of the book series: Contemporary Cardiology™ ((CONCARD))

  • 1657 Accesses

Pulmonary hypertension refers to a variety of conditions characterized by elevations in pulmonary arterial pressure. Major advances in the understanding of PH have led to the current classification in which PH diseases are grouped into five categories according to cause and therapeutic strategy, with each category subdivided to reflect diverse underlying etiologies and sites of injury. The five major categories of the Venice classification include PAH, pulmonary venous hypertension associated with left heart disease, PH associated with hypoxemia, PH due to chronic thrombotic and/or embolic disease, and PH due to miscellaneous causes. One notable change in the current nomenclature is that the term “idiopathic pulmonary arterial hypertension” (IPAH) has replaced “primary pulmonary hypertension.” The WHO functional classification standardizes the comparison of clinical severity among patients with PH. Experts have embraced both the clinical and functional classification systems. Future attempts at refining the classification of this constellation of diseases are likely to embrace new insights into the molecular mechanisms and genetics of PH.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hatano S, Strasser T, eds. Primary pulmonary hypertension. Report on a WHO meeting. Geneva: World Health Organization; 1975.

    Google Scholar 

  2. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):5S–12S.

    Article  PubMed  Google Scholar 

  3. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 1994;105(2 Suppl):37S–41S.

    Google Scholar 

  4. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107(2):216–23.

    PubMed  CAS  Google Scholar 

  5. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115(5):343–9.

    PubMed  CAS  Google Scholar 

  6. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998;101:927–34.

    Article  PubMed  CAS  Google Scholar 

  7. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med 1951;11(6):686–705.

    Article  PubMed  CAS  Google Scholar 

  8. Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345(5):319–24.

    Article  PubMed  CAS  Google Scholar 

  9. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106(12):1477–82.

    Article  PubMed  CAS  Google Scholar 

  10. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000;37(10):741–5.

    Article  PubMed  CAS  Google Scholar 

  11. Loyd JE, Primm RK, Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis 1984;129(1):194–7.

    PubMed  CAS  Google Scholar 

  12. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA, 3rd, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995;152(1):93–7.

    PubMed  CAS  Google Scholar 

  13. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26(1):81–4.

    Article  PubMed  CAS  Google Scholar 

  14. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67(3):737–44.

    Article  PubMed  CAS  Google Scholar 

  15. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345(5):325–34.

    Article  PubMed  CAS  Google Scholar 

  16. Hoeper MM. Pulmonary hypertension in collagen vascular disease. Eur Respir J 2002;19(3):571–6.

    Article  PubMed  CAS  Google Scholar 

  17. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132(6):425–34.

    PubMed  CAS  Google Scholar 

  18. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003;167(4):580–6.

    Article  PubMed  Google Scholar 

  19. Eisenmenger V. Die angeboren defects des kammerscheidewand des herzen. Z Klin Med 1897;32:1–28.

    Google Scholar 

  20. Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993;87(2 Suppl):I38–51.

    PubMed  CAS  Google Scholar 

  21. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996;15(1 Pt 1):100–5.

    PubMed  CAS  Google Scholar 

  22. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Fac-tors relating to deterioration and death. Eur Heart J 1998;19(12):1845–55.

    Article  PubMed  CAS  Google Scholar 

  23. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983;127(4):437–41.

    PubMed  CAS  Google Scholar 

  24. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100(2):520–8.

    PubMed  CAS  Google Scholar 

  25. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997;3(5):494–500.

    Article  PubMed  CAS  Google Scholar 

  26. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987;10(6):1233–8.

    Article  PubMed  CAS  Google Scholar 

  27. Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11(5):1153–66.

    Article  PubMed  CAS  Google Scholar 

  28. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30(3):641–8.

    Article  PubMed  CAS  Google Scholar 

  29. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;10(2):174–82.

    Article  PubMed  Google Scholar 

  30. Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155(3):990–5.

    PubMed  CAS  Google Scholar 

  31. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991;100(5):1268–71.

    Article  PubMed  CAS  Google Scholar 

  32. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167(10):1433–9.

    Article  PubMed  Google Scholar 

  33. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004;38(8):1178–85.

    Article  PubMed  Google Scholar 

  34. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985;27(2–3):160–71.

    PubMed  CAS  Google Scholar 

  35. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335(9):609–16.

    Article  PubMed  CAS  Google Scholar 

  36. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000;117(3):870–4.

    Article  PubMed  CAS  Google Scholar 

  37. Holcomb BW, Jr., Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000;118(6):1671–9.

    Article  PubMed  Google Scholar 

  38. Dufour B, Maitre S, Humbert M, Capron F, Simonneau G, Musset D. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998;171(5):1321–4.

    PubMed  CAS  Google Scholar 

  39. Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998;113(1):237–40.

    Article  PubMed  CAS  Google Scholar 

  40. Humbert M, Maitre S, Capron F, Rain B, Musset D, Simonneau G. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998;157(5 Pt 1):1681–5.

    PubMed  CAS  Google Scholar 

  41. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105(1 Pt 1):14–20.

    Article  PubMed  CAS  Google Scholar 

  42. Roberts JD, Jr., Fineman JR, Morin FC, 3rd, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997;336(9):605–10.

    Article  PubMed  CAS  Google Scholar 

  43. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134(1):44–54.

    Article  PubMed  CAS  Google Scholar 

  44. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 2003;108(18):2184–90.

    Article  PubMed  CAS  Google Scholar 

  45. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000;161(1):216–23.

    PubMed  CAS  Google Scholar 

  46. Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004;43(12 Suppl S):33S–9S.

    Article  PubMed  CAS  Google Scholar 

  47. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):25S–32S.

    Article  PubMed  Google Scholar 

  48. Voordes CG, Kuipers JR, Elema JD. Familial pulmonary veno-occlusive disease: a case report. Thorax 1977;32(6):763–6.

    Article  PubMed  CAS  Google Scholar 

  49. Langleben D, Heneghan JM, Batten AP, et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med 1988;109(2):106–9.

    PubMed  CAS  Google Scholar 

  50. Runo JR, Vnencak-Jones CL, Prince M, et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003;167(6):889–94.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. C. William Hargett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor F. Tapson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Pulmonary, Critical Care and Sleep Medicine Tufts Medical Center, Boston, MA

    Nicholas S. Hill MD

  2. Pulmonary Center, Boston University, Boston, MA

    Harrison W. Farber MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Hargett, C.W., Tapson, V.F. (2008). Classification of Pulmonary Hypertension. In: Hill, N.S., Farber, H.W. (eds) Pulmonary Hypertension. Contemporary Cardiology™. Humana Press. https://doi.org/10.1007/978-1-60327-075-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-075-5_2

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-661-0

  • Online ISBN: 978-1-60327-075-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation